Category Archives: Nursing and Health

NSF-approved Biographical Sketch and Current and Pending Support Formats

Posted on by

A Notice From the National Science Foundation:

Dear Colleagues: We are pleased to announce the availability of both NSF-approved formats for the Biographical Sketch and Current and Pending Support sections of National Science Foundation (NSF) proposals that fall under the revised Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 20-1) (see the February 6, 2020 webinar for complete details on all revisions to the PAPPG).

Although use of an NSF-approved format for submission of these proposal sections is not required until implementation of the revised PAPPG (NSF 20-1) on June 1, 2020, NSF is encouraging proposers to begin using the NSF-approved formats now. NSF values the feedback from the research community, and we would like to hear about your experience with the new NSF-approved formats. Information about how to provide feedback is included below.

Use of an NSF-approved format aims to reduce administrative burden and improve efficiencies by providing proposers with a compliant and reusable way to maintain this information for subsequent proposal submissions to NSF, while also ensuring that the information is submitted in a standard and searchable composition.

NSF-approved Formats

  • SciENcv: NSF has partnered with the National Institutes of Health (NIH) to use SciENcv: Science Experts Network Curriculum Vitae as an NSF-approved format for use in preparation of both the Biographical Sketch and Current and Pending Support sections of an NSF proposal. SciENcv will produce an NSF-compliant PDF version of the documents which proposers can save and submit as part of their proposals via FastLane, Research.gov or Grants.gov. Additional information about the NSF-approved SciENcv formats is available on the NSF biographical sketch and current and pending support websites. 

The SciENcv tool integrates with ORCID, enabling proposers to populate their Biographical Sketches by importing data directly from their ORCID records rather than having to manually enter all the required information. Additionally, Biographical Sketch data maintained in SciENcv can be quickly and easily updated on an ongoing basis for subsequent proposal submissions.

  • NSF Fillable PDF: NSF is also providing a fillable PDF as an NSF-approved format for use to prepare both the Biographical Sketch and Current and Pending Support sections of an NSF proposal. Proposers can download the respective fillable PDF form from the NSF biographical sketch and current and pending support websites and then submit the completed forms as part of their proposals via FastLane, Research.gov or Grants.gov. Note that the NSF fillable PDF for the Biographical Sketch does not integrate with ORCID. 

It is important to note that beginning June 1, 2020, proposers will be required to use one of the NSF-approved formats for both the Biographical Sketch and Current and Pending Support sections of NSF proposals. Proposals submitted via FastLane, Research.gov and Grants.gov will be compliance checked to ensure that the documents were prepared in accordance with this new policy.

Although not required for proposal submission until June 1, 2020, we hope that you will start using the NSF-approved formats for Biographical Sketch and Current and Pending Support as soon as possible. If you have any feedback that would help us make improvements to the two formats in the future, please let us know. Feedback may be submitted by email to policy@nsf.gov or via the Research.gov Feedback page (select “Biographical Sketch” or “Current & Pending Support” under the Site Area dropdown menu).

To assist the community about these new requirements and to start using SciENcv now, NSF and NIH are planning to conduct a joint webinar that will include a walk-through of how to prepare the Biographical Sketch and Current and Pending Support documents in SciENcv. Information will be provided as soon as it is available, and we encourage you to sign up for notifications.  

We also invite you to participate in the next NSF Electronic Research Administration (ERA) Forum on May 14, 2020 at 1:00PM – 2:30PM EDT where we will discuss the NSF-approved format requirements, as well as the new capability to prepare and submit separately submitted collaborative proposals in Research.gov. To sign up for ERA Forum notifications including registration availability for the May 14 event, please send a blank email to NSF-ERA-FORUM-subscribe-request@listserv.nsf.gov and you will be automatically enrolled.

The following training resources are now available, and NSF will continue to keep the community informed as additional resources are released.

Biographical Sketch Resources

Current and Pending Support Resources

Questions? Policy-related questions should be directed to policy@nsf.gov. If you have technical or IT system-related questions, please contact the NSF Help Desk at 1-800-673-6188 (7:00 AM – 9:00 PM ET; Monday – Friday except federal holidays) or via fastlane@nsf.gov.

Regards, National Science Foundation

Department of Defense Orthotics and Prosthetics Outcomes Research Program

Posted on by

The FY20 Defense Appropriation Act provides $15 million to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology as directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 OPORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. OPORP supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service Members and Veterans with limb loss and/or limb impairment. The intent of this research is to generate clinically useful evidence that will enhance and optimize patient outcomes. Applications submitted to the FY20 OPORP must address at least one of the following Focus Areas:

  • Orthoses or Prostheses Form: Optimize patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
  • Orthoses or Prostheses Fit: Optimize patient outcomes related to human-device interface through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
  • Orthoses or Prostheses Function: Optimize patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

Clinical Research Award – Letter of Intent due June 10, 2020

Independent investigators at all academic levels (or equivalent):

  • Supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service Members, Veterans, and other individuals with limb loss and/or limb impairment.
  • Supported research is intended to generate clinically useful evidence with potential to enhance and optimize patient outcomes.
  • Multidisciplinary collaboration among academics, industry, patient advocacy, the military Services, the Department of Veterans Affairs (VA), and/or other Federal Government agencies is highly encouraged.
  • Applications submitted to the FY20 OPORP CRA must address one or more of the FY20 OPORP Focus Areas.
  • Preclinical studies using animals are not allowed.
  • Clinical trials are not allowed.
  • The FY20 CRA offers two funding levels:
    • Funding Level 1: Maximum funding of $350,000 for total costs (direct plus indirect costs). Maximum period of performance is 2 years.
    • Funding Level 2: Maximum funding of $2,000,000 for total costs (direct plus indirect costs). Maximum period of performance is 4 years.

Clinical Trial Award – Letter of Intent due June 10, 2020

Independent investigators at all academic levels (or equivalent:

  • Supports implementation of clinical trials with the potential to have a significant impact on improving the health and well-being of Service Members, Veterans, and other individuals living with limb loss and/or limb impairment.
  • Supports clinical trials that evaluate orthoses and/or prostheses using patient-centric outcomes for the purpose of generating clinically useful evidence to enhance and optimize patient outcomes.
  • Multidisciplinary collaborations among academia, industry, patient advocacy, the Military Services, VA, and/or other Federal Government agencies is highly encouraged.
  • Applications submitted to the FY20 OPORP CTA must address one or more of the FY20 OPORP Focus Areas.
  • Preclinical research is not allowed.
  • The FY20 CTA offers two funding levels:
  • Funding Level 1
    • Funding Level 1 supports pilot clinical trials which are exploratory and involve limited human exposure with the potential to make significant advancement toward clinical translation. Preliminary data are allowed but not required. Maximum funding of $350,000 for total costs (direct plus indirect costs). Maximum period of performance is 2 years
    • Funding Level 2 supports clinical trials with the potential to make significant advancement toward clinical translation. Preliminary data relevant to the proposed clinical trial are required. Maximum funding of $4,000,000 for total costs (direct plus indirect costs). Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website.


Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

Posted on by

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance pre-doctoral and post-doctoral research training, including short term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda.

Research training programs are expected to incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term predoctoral research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training.

Department of Defense Peer Reviewed Orthopaedic Research Program

Posted on by

The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) to support innovative, high-impact, clinically-relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 PRORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY20 PRORP must address one or more of the following FY20 Focus Areas:

  • Compartment Syndrome: Novel treatment strategies to improve current diagnoses for compartment syndrome. Alternatives to intracompartmental pressure measurements are encouraged.
  • Limb Stabilization and Protection: Development and/or clinical assessment of rapid limb stabilization and novel wound protectants for severely wounded limbs to enable transport at the point of need.
  • Orthotic Devices: Refinement of high-performance novel orthotic devices designed to enhance whole person performance and decrease pain in patients with limb salvage and impairment.
  • Osseointegration: Identification of best practices to address infection, rejection, and/or failure of percutaneous osseointegrated prosthetic limbs. 
  • Retention Strategies: Development, optimization, and/or validation of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty for common combat-related musculoskeletal injuries.  Biomarker studies are excluded.  The current standard of care must be noted.  The rehabilitation strategy and the standard of care must be specified, as applicable.
    • Point of Injury: Battlefield-feasible strategies that can be utilized at or near the point of injury to allow an injured Service member to remain on duty and stay on mission without the need for immediate evacuation
    • Point of Duty: Strategies that can be utilized along the continuum of care to allow an injured Service member to return to duty without separation from Service.
  • Tissue Regeneration Therapeutics: Development of advanced tissue regeneration therapeutics in nerve, muscle (to include volumetric muscle loss), and/or composite tissue for the restoration of traumatically injured extremities.  Isolated bone or cartilage tissue engineering studies are excluded.
  • Translation of Early Findings: Translation of early research findings in the orthopaedic surgical care topic areas listed below to move the research toward clinical trials and clinical practice.
    • Soft Tissue Trauma: Strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments for anterior cruciate ligament (ACL) or shoulder instability only, to optimize return to duty, work, or reintegration
    • Fracture-Related Infection: Strategies to decrease the burden of fracture-related infections (may include prevention, early detection, or improved eradication).  Alternatives to systemic and/or local antibiotic delivery are encouraged. 

https://cdmrp.army.mil/funding/prorp

Applied Research Award – Preproposal due May 27, 2020. Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with musculo-skeletal injuries sustained during combat or combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work.
  • Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
  • Clinical research and clinical trials are not allowed under this award mechanism.
  • Applications must address one of the following FY20 PRORP Focus Areas:
    • Limb Stabilization and Protection
    • Retention Strategies
      • Point of Injury
      • Return to Duty
  • Osseointegration

Maximum funding of $725,000 for total costs (includes direct and indirect costs). Maximum period of performance is 3 years.

Clinical Trial Award – Preproposal due May 27, 2020.Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.
  • Funding must support a clinical trial and may not be used for preclinical research studies.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
  • Applications must address one the following FY20 PRORP Focus Areas:
    • Limb Stabilization and Protection
    • Retention Strategies
      • Point of Injury
      • Return to Duty
    • Translation of Early Findings
      • Soft Tissue Trauma
      • Fracture-Related Infection

Funding Level 1:Maximum funding of $2.25M for total costs. (includes direct and indirect costs). Maximum period of performance is 4 years.

Funding Level 2 (Translation of Early Findings – Soft Tissue Trauma Focus Area with Rehabilitation Option): Maximum funding of $2.75M for total costs (includes direct and indirect costs). Maximum period of performance is 4 years.

Clinical Translational Research Award – Preproposal is due May 27, 2020. Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale, randomized, controlled clinical trial.
  • Funding must support clinical research studies involving humans.
  • Preliminary or published data relevant to the proposed research project are required.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 12 months of the award date.
  • Applications must address one of the following FY19 PRORP CTRA Focus Areas:
    • Retention Strategies
      • Point of Injury
      • Return to Duty
    • Tissue Regeneration Therapeutics
    • Compartment Syndrome
    • Osseointegration
    • Orthotic Devices

Maximum funding of $1.5M for total costs (including direct and indirect costs). Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website.

BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical Research and Development

Posted on by

This BAA is intended to solicit extramural research and development ideas using the authority provided by United States Code, Title 10, Section 2358. This BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation 6.102(d) (2) and 35.016 and in DoD Grant and Agreement Regulations (DoDGARs) 22.315. In accordance with FAR 6.102, projects funded under this BAA must be for basic and applied research to support scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. Research and development funding through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge.

This BAA provides a general description of USSOCOM’s research and development programs, including research areas of interest, evaluation and selection criteria, pre-proposal/pre-application and full proposal/application preparation instructions, and general administrative information. Submission of a pre-proposal/pre-application is required. After review, if the USSOCOM is interested in receiving a full proposal/application, the Applicant or Offeror will be invited to submit a full proposal or full application. Specific submission information and additional administrative requirements can be found in the document titled “General Submission Instructions” available in Grants.gov along with this BAA.

USSOCOM utilizes the tools and processes provided by Congressionally Directed Medical Research Programs (CDMRP). The CDMRP manages the electronic Biomedical Research Application Portal (eBRAP) system and retrieval and processing of full proposal/application submissions from Grants.gov. Refer to Section II.G, Agency Contacts, for additional information.